Clinical Trial Update: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating selumetinib plus docetaxel for second-line KRAS-positive non-small cell lung cancer; results were posted in 2017 and the study remains …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2017-08-29